Search Results - "Ragde, H."

Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen by Murphy, G., Tjoa, B., Ragde, H., Kenny, G., Boynton, A.

“…BACKGROUND Conventional treatment for metastatic prostate cancer have failed to demonstrate curative potential in all patients. Investigations involving the…”
Get full text

Safety and efficacy of dendritic cell (DC)-based cryoimmunotherapy (CryoIT) combined with checkpoint inhibition in a prospective non-randomized Phase I trial of metastatic castration resistant prostate cancer (mCRPC) by Thomsen, L.C.V., Honoré, A., Almås, B., Reisæter, L.A.R., Førde, K., Kristoffersen, E.K., Kaada, S.H., Melve, G.K., Helle, S.I., Kvalheim, G., Azeem, W., Olsen, J.R., Halvorsen, O.J., Akslen, L.A., Bahn, D., Pantel, K., Riethdorf, S., Ragde, H., Gjertsen, B.T., Øyan, A.M., Kalland, K.H., Beisland, C.

Get full text

Follow-up evaluation of a phase II prostate cancer vaccine trial by Tjoa, B.A., Simmons, S.J., Elgamal, A., Rogers, M., Ragde, H., Kenny, G.M., Troychak, M.J., Boynton, A.L., Murphy, G.P.

“…BACKGROUND A phase II trial, involving infusions of autologous dendritic cells (DC) and two human histocompatibility antigen (HLA‐A2)‐specific…”
Get full text

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease by Murphy, G.P., Tjoa, B.A., Simmons, S.J., Jarisch, J., Bowes, V.A., Ragde, H., Rogers, M., Elgamal, A., Kenny, G.M., Cobb, O.E., Ireton, R.C., Troychak, M.J., Salgaller, M.L., Boynton, A.L.

“…BACKGROUND A phase II trial was conducted to assess the efficacy of infusions of dendritic cells (DC) and two HLA‐A2‐specific PSMA peptides (PSM‐P1 and ‐P2)…”
Get full text

Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment by Murphy, G.P., Tjoa, B.A., Simmons, S.J., Ragde, H., Rogers, M., Elgamal, A., Kenny, G.M., Troychak, M.J., Salgaller, M.L., Boynton, A.L.

“…BACKGROUND A phase II trial was conducted to assess the efficacy of infusions of dendritic cells (DC) and two HLA‐A2‐specific prostate‐specific membrane…”
Get full text

Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides by Tjoa, B.A., Simmons, S.J., Bowes, V.A., Ragde, H., Rogers, M., Elgamal, A., Kenny, G.M., Cobb, O.E., Ireton, R.C., Troychak, M.J., Salgaller, M.L., Boynton, A.L., Murphy, G.P.

“…BACKGROUND A phase I trial involving patients with advanced prostate cancer was conducted to assess the safe administration of dendritic cells (DC) and…”
Get full text

Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides by Tjoa, B.A., Erickson, S.J., Bowes, V.A., Ragde, H., Kenny, G.M., Cobb, O.E., Ireton, R.C., Troychak, M.J., Boynton, A.L., Murphy, G.P.

“…BACKGROUND We recently conducted a phase I clinical trial administering autologous dendritic cells pulsed with prostate‐specific membrane antigen (PSMA)…”
Get full text

Modern prostate brachytherapy by Ragde, H, Grado, G. L, Nadir, B, Elgamal, A. A

“…Of all the treatment options available for men with organ‐confined prostate cancer, brachytherapy—permament implantation of radioactive seeds into the prostate…”
Get full text

GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial by Simmons, S.J., Tjoa, B.A., Rogers, M., Elgamal, A., Kenny, G.M., Ragde, H., Troychak, M.J., Boynton, A.L., Murphy, G.P.

“…BACKGROUND Recombinant human granulocyte‐macrophage colony‐stimulating factor (GM‐CSF; Leukine® [sargramostim], Immunex Corp., Seattle, WA) was administered to…”
Get full text

Dendritic cell-based immunotherapy of prostate cancer by Salgaller, M L, Tjoa, B A, Lodge, P A, Ragde, H, Kenny, G, Boynton, A, Murphy, G P

“…The immunotherapy of cancer, based on eliciting or enhancing the body's own capacity to mount an effective antitumor response, has produced encouraging early…”
Get full text

Should brachytherapy be considered a therapeutic option in localized prostate cancer? by Blasko, J C, Ragde, H, Luse, R W, Sylvester, J E, Cavanagh, W, Grimm, P D

“…Contemporary prostate brachytherapy incorporates advances in computer analysis, imaging technology, and delivery apparatus, allowing exacting and reproducible…”
Get more information

Prostate cancer brachytherapy by Ragde, H

Get full text

Brachytherapy for prostate cancer by Porter, A. T, Blasko, J. C, Grimm, P. D, Reddy, S. M, Ragde, H

“…Brachytherapy is one of the oldest techniques of radiation therapy for prostate cancer. However, its use has been controversial due to mixed results with older…”
Get full text

Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients by Murphy, G, Ragde, H, Kenny, G, Barren, 3rd, R, Erickson, S, Tjoa, B, Boynton, A, Holmes, E, Gilbaugh, J, Douglas, T

“…PSA (prostate specific antigen) and PSMA (prostate specific membrane antigen) serum levels were determined in over 235 prostate cancer patients from 8…”
Get more information

Transperineal ultrasound-guided implantation of the prostate: morbidity and complications by Blasko, J C, Ragde, H, Grimm, P D

“…Two hundred and seventy four patients with early carcinoma of the prostate were treated by ultrasound-guided transperineal I-125 implantation. One hundred and…”
Get more information

Does brachytherapy have a role in the treatment of prostate cancer? by Grimm, P D, Blasko, J C, Ragde, H, Sylvester, J, Clarke, D

“…The goal of radiation therapy is to deliver a high dose to the tumor while preserving normal surrounding tissue. For early-stage prostate cancer, the ultimate…”
Get more information

Measurement of prostate-specific membrane antigen in the serum with a new antibody by Murphy, G. P., Tino, W. T., Holmes, E. H., Boynton, A. L., Erickson, S. J., Bowes, V. A., Barren, R. J., Tjoa, B. A., Misrock, S. L., Ragde, H., Kenny, G. M.

“…Work to date has identified prostate‐specific membrane antigen (PSMA) as a membrane‐bound glycoprotein with high specificity for prostatic epithelial cells…”
Get full text

Workgroup 3: Current prognostic factors and their relevance to staging by Hutter, Robert V. P., Montie, James E., Busch, Christer, Grignon, David J., Lieber, Michael, Logothetis, Christopher, Ragde, Haakon, Reuter, Victor E.

Get full text

Ultrasound-guided prostate biopsy. Biopty gun superior to aspiration by Ragde, H, Aldape, H C, Bagley, Jr, C M

“…We used a 7 MHz transrectal ultrasound scanner to perform guided core biopsy and aspiration cytologies on 292 patients with findings suspicious for prostate…”
Get more information

Radiotherapy for prostate cancer: Brachytherapy alone by Ragde, Haakon

Get full text